Filtered By:
Condition: Stroke
Drug: Metformin

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 446 results found since Jan 2013.

Vascularization Pattern After Ischemic Stroke is Different in Control Versus Diabetic Rats: Relevance to Stroke Recovery Basic Sciences
Conclusions— Diabetes mellitus impairs poststroke reparative neovascularization and impedes the recovery. Glycemic control after stroke can improve neurovascular repair and improve functional outcome.
Source: Stroke - September 23, 2013 Category: Neurology Authors: Prakash, R., Li, W., Qu, Z., Johnson, M. A., Fagan, S. C., Ergul, A. Tags: Type 2 diabetes, Behavioral Changes and Stroke, Other imaging, Other Vascular biology Basic Sciences Source Type: research

Metformin-inclusive Therapy Reduces the Risk of Stroke in Patients with Diabetes: A 4-Year Follow-up Study
Metformin is a kind of oral hypoglycemic agents commonly prescribed to patients with diabetes mellitus. Although past studies had proven its protective effect on cardiovascular risk and related mortality, the evidence of metformin on stroke prevention was still insufficient and conflicting. Our study randomly selected 14,856 patients with diabetes from the database provided by the Taiwan National Health Research Institute, and 2 cohorts were formulated according to whether metformin was in the prescription record. All cases were followed up for 4 years to track their stroke incidence. As a result, 701 (17.5%) of 3999 diabe...
Source: Journal of Stroke and Cerebrovascular Diseases - October 11, 2013 Category: Neurology Authors: Yuan-Yang Cheng, Hsin-Bang Leu, Tzeng-Ji Chen, Chen-Ling Chen, Chia-Hua Kuo, Shin-Da Lee, Chung-Lan Kao Tags: Original Articles Source Type: research

Effect of metformin on outcome after acute ischemic stroke in patients with type 2 diabetes mellitus
Diabetes mellitus is a well-known risk factor for ischemic stroke and is associated with unfavorable outcome after stroke. Metformin is recommended as first-line treatment in these patients. Pre-stroke metformin use might have neuroprotective properties resulting in reduced stroke severity. However, results of the effects of pre-stroke metformin use on functional outcome are conflicting and has not been previously described in patients with type 2 diabetes mellitus regardless of stroke severity or revascularization treatment.
Source: Journal of Stroke and Cerebrovascular Diseases - August 1, 2022 Category: Neurology Authors: C.J.B.A. Kersten, I.L.H. Knottnerus, E. Heijmans, M. Haalboom, A.A.M. Zandbergen, H.M. den Hertog Source Type: research

Safety and feasibiLIty of Metformin in patients with Impaired glucose Tolerance and a recent TIA or minor ischemic stroke (LIMIT) trial – a multicenter, randomized, open‐label phase II trial
ConclusionsTreatment with metformin in patients with TIA or minor ischemic stroke and impaired glucose tolerance is safe, but leads to minor side effects. If tolerated, it may lead to a significant reduction in post‐load glucose levels. This suggests that the role of metformin as potential therapeutic agent for secondary stroke prevention should be further explored.
Source: International Journal of Stroke - March 15, 2013 Category: Neurology Authors: Heleen M. Hertog, S. E. Vermeer, A. A. M. Zandbergen, Sefanja Achterberg, Diederik W. J. Dippel, Ale Algra, L. J. Kappelle, Peter J. Koudstaal Tags: Protocols Source Type: research

Impact of Metformin on the Severity and Outcomes of Acute Ischemic Stroke in Patients with Type 2 Diabetes Mellitus
This study evaluated the effects of metformin on stroke severity and outcomes in acute ischemic stroke patients with type 2 DM.
Source: Journal of Stroke and Cerebrovascular Diseases - December 22, 2015 Category: Neurology Authors: Yohei Mima, Takahiro Kuwashiro, Masahiro Yasaka, Yuichiro Tsurusaki, Asako Nakamura, Yoshiyuki Wakugawa, Yasushi Okada Source Type: research

In reply to the letter to the editor reading: Mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes diagnosed after metformin-triggered stroke-like episodes
We are grateful to Josef Finsterer for his comments on our recent report regarding mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) diagnosed after metformin-triggered stroke-like episodes (SLEs).1 In his letter to the editor, several limitations regarding our study were raised.
Source: Journal of Stroke and Cerebrovascular Diseases - April 19, 2023 Category: Neurology Authors: Keishu Murakami, Ken Sakamoto, Hiroshi Ishiguchi, Hidefumi Ito Tags: Letter to the Editor Source Type: research

Letter to the Editor regarding “Mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes diagnosed after metformin-triggered stroke-like episodes”
We read with interest the article by Murakami et al. about a 40 years-old male with mitochondrial encephalopathy, lactic acidosis, and stroke-like episode (MELAS) syndrome due to the variant m.3243A>G with a heteroplasmy rate of 27%, in whom metformin was suspected to have triggered a stroke-like episode (SLE), the phenotypic hallmark of MELAS.1 Metformin was replaced by sitagliptin and the patient was discharged in a stable condition after three weeks.1 The study is excellent, but has limitations that are objectionable and should be discussed.
Source: Journal of Stroke and Cerebrovascular Diseases - April 20, 2023 Category: Neurology Authors: Josef Finsterer Tags: Letter to the Editor Source Type: research

Impact of glucose-lowering therapies on risk of stroke in type 2 diabetes.
Abstract Patients with type 2 diabetes (T2D) have an increased risk of stroke compared with people without diabetes. However, the effects of glucose-lowering drugs on risk of ischaemic stroke in T2D have been less extensively investigated than in coronary heart disease. Some evidence, including the UKPDS, has suggested a reduced risk of stroke with metformin, although the number of studies is limited. Inhibition of the KATP channels increases ischaemic brain lesions in animals. This is in agreement with a recent meta-analysis showing an increased risk of stroke with sulphonylureas vs. various comparators as both m...
Source: Diabetes and Metabolism - May 15, 2017 Category: Endocrinology Authors: Bonnet F, Scheen AJ Tags: Diabetes Metab Source Type: research

Sex differences in outcomes after stroke among patients with low total cholesterol levels: a large hospital-based prospective study
ConclusionsThese findings suggest that patients (both men and women) with atherothrombotic infarction who have low TC levels would not benefit from receiving statin treatment. Therefore, it is crucial to explore the impact of statin treatment on outcomes in Asian patients, especially Chinese patients with atherothrombotic and low TC levels, in order to improve outcomes after stroke and reduce the disease burden.
Source: Biology of Sex Differences - November 23, 2016 Category: Biology Source Type: research

Diabetes: Chronic Metformin Treatment and Outcome Following Acute Stroke
ConclusionSimilar to previous reports, our study shows that diabetes adversely affects stroke outcome. The use of prior metformin is associated with better outcome in patients with ischemic stroke and results in lower mortality. The positive effects of metformin require further research to better understand its mechanism.
Source: Frontiers in Neurology - April 26, 2022 Category: Neurology Source Type: research

Antidiabetic drugs and stroke risk. Current evidence.
Abstract Cardiovascular disease (CVD) is the major cause of morbidity and mortality for individuals with type 2 diabetes (T2D). In particular, the risk for stroke is twice that of patients without diabetes, and diabetes may be responsible for >8% of first ischemic strokes. Therefore, the way to prevent stroke in these patients has become an important issue. Traditionally, glucose-lowering drugs had not been shown to protect against stroke. Moreover, several antidiabetic drugs (i.e., sulfonylureas, rosiglitazone) have been reported to be associated with increased risks of CVD and stroke. On the contrary, data on...
Source: European Journal of Internal Medicine - September 20, 2017 Category: Internal Medicine Authors: Castilla-Guerra L, Fernandez-Moreno MDC, Leon-Jimenez D, Carmona-Nimo E Tags: Eur J Intern Med Source Type: research

Stroke risk in treatment of type 2 diabetes in China: a 7 year retrospective cohort study
Publication date: November 2016 Source:The Lancet Diabetes & Endocrinology, Volume 4, Supplement 1 Author(s): Rui Liu, Qing Wang, Vivian Szeto, Andrew Barszczyk, Tianru Jin, Edoardo Mannucci, Hong-Shuo Sun, Zhong-Ping Feng Background Diabetes and stroke are leading causes of death and disability, and major public health concerns in China, which accounts for 25% of patients with diabetes worldwide. Type 2 diabetes is an independent risk factor for cerebral ischaemia and accounts for about 20% of stroke cases. We previously showed that KATP channel activation provides neuroprotection against cerebral ischaemia and t...
Source: The Lancet Diabetes and Endocrinology - November 17, 2016 Category: Endocrinology Source Type: research

Involvement of arterial baroreflex and nicotinic acetylcholine receptor α7 subunit pathway in the protection of metformin against stroke in stroke-prone spontaneously hypertensive rats.
In conclusion, Met improved the arterial baroreflex function, and then enhancing cholinergic anti-inflammatory pathway in an α7nAChR-dependent manner, thereby effectively prevent ischemic induced brain injury and delayed stroke onset in SHRSP. PMID: 28132912 [PubMed - as supplied by publisher]
Source: European Journal of Pharmacology - January 25, 2017 Category: Drugs & Pharmacology Authors: Guo JM, Zhang L, Niu XC, Shu H, Wang L, Su DF, Zhang Y, Liu AJ, Zhu DQ, Xu JJ Tags: Eur J Pharmacol Source Type: research

Attenuation of Myeloid Specific TGF β Signaling Induces Inflammatory Cerebrovascular Disease and Stroke.
Conclusions: Our studies show that TGFβ signaling in myeloid cells is required for maintenance of vascular health, and provide insight into inflammation-mediated cerebrovascular disease and stroke. PMID: 29051340 [PubMed - as supplied by publisher]
Source: Circulation Research - October 19, 2017 Category: Cardiology Authors: Hollander MC, Latour LL, Yang D, Ishii H, Xiao Z, Min Y, Ray-Choudhury A, Munasinghe J, Merchant AS, Lin PC, Hallenbeck J, Boehm M, Yang L Tags: Circ Res Source Type: research

Association of glucose-lowering drugs with incident stroke and transient ischaemic attacks in primary care patients with type 2 diabetes: disease analyzer database
ConclusionsTreatment with SGLT2 inhibitors or GLP-1 receptor agonists might reduce non-fatal stroke/TIA in persons with newly diagnosed type 2 diabetes.
Source: Acta Diabetologica - August 6, 2022 Category: Endocrinology Source Type: research